X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4232) 4232
Newspaper Article (1010) 1010
Newsletter (408) 408
Magazine Article (21) 21
Trade Publication Article (20) 20
Book Chapter (15) 15
Web Resource (10) 10
Book / eBook (5) 5
Dissertation (2) 2
Book Review (1) 1
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mesothelioma (3830) 3830
humans (3132) 3132
oncology (2186) 2186
index medicus (1904) 1904
cancer (1820) 1820
mesothelioma - drug therapy (1647) 1647
chemotherapy (1512) 1512
female (1440) 1440
male (1398) 1398
middle aged (1138) 1138
mesothelioma - pathology (1022) 1022
aged (1012) 1012
pleural neoplasms - drug therapy (878) 878
tumors (851) 851
research (772) 772
malignant pleural mesothelioma (771) 771
adult (769) 769
animals (742) 742
cancer therapies (719) 719
care and treatment (679) 679
cisplatin (667) 667
cell line, tumor (637) 637
antineoplastic combined chemotherapy protocols - therapeutic use (596) 596
immunotherapy (572) 572
lung cancer (572) 572
clinical trials (557) 557
malignant mesothelioma (556) 556
apoptosis (539) 539
surgery (532) 532
prognosis (523) 523
lung neoplasms - drug therapy (520) 520
pleural neoplasms - pathology (511) 511
respiratory system (509) 509
treatment outcome (500) 500
mice (488) 488
antineoplastic agents - therapeutic use (451) 451
mesothelioma - metabolism (449) 449
medical research (448) 448
pemetrexed (443) 443
mesothelioma - therapy (433) 433
asbestos (413) 413
patients (402) 402
expression (398) 398
cisplatin - administration & dosage (395) 395
lung neoplasms - pathology (383) 383
health aspects (381) 381
combined modality therapy (379) 379
medical prognosis (365) 365
pleural mesothelioma (360) 360
mesothelioma - mortality (358) 358
analysis (350) 350
mesothelioma - genetics (343) 343
metastasis (328) 328
survival (328) 328
proteins (320) 320
peritoneal neoplasms - drug therapy (318) 318
mesothelioma - surgery (317) 317
therapy (306) 306
guanine - analogs & derivatives (302) 302
studies (296) 296
aged, 80 and over (291) 291
antineoplastic agents - pharmacology (285) 285
diagnosis (281) 281
drug therapy (266) 266
ovarian cancer (265) 265
mesothelioma - diagnosis (261) 261
lung-cancer (257) 257
gene expression (254) 254
medicine (252) 252
survival rate (251) 251
apoptosis - drug effects (250) 250
pharmacology & pharmacy (245) 245
cell lung-cancer (239) 239
pleural neoplasms - mortality (235) 235
kinases (234) 234
retrospective studies (222) 222
medicine & public health (221) 221
survival analysis (221) 221
cell biology (220) 220
biochemistry & molecular biology (216) 216
immunohistochemistry (210) 210
neoplasm staging (208) 208
pleural neoplasms - therapy (208) 208
cell proliferation - drug effects (207) 207
phase-ii (205) 205
pleural neoplasms - surgery (204) 204
extrapleural pneumonectomy (203) 203
hematology, oncology and palliative medicine (202) 202
lung neoplasms - metabolism (200) 200
combination (199) 199
phase-ii trial (199) 199
antineoplastic agents - administration & dosage (192) 192
development and progression (190) 190
pleural neoplasms - metabolism (188) 188
tumor cells, cultured (188) 188
research article (187) 187
medicine, research & experimental (184) 184
gemcitabine (181) 181
radiotherapy (181) 181
cells (180) 180
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5546) 5546
French (67) 67
Japanese (51) 51
German (41) 41
Chinese (10) 10
Italian (10) 10
Russian (8) 8
Spanish (8) 8
Polish (4) 4
Dutch (2) 2
Romanian (2) 2
Turkish (2) 2
Czech (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. e254 - e262
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 68, pp. 1 - 10
.... Results Forty-one patients with advanced solid tumours refractory to standard therapies and with adequate organ function were recruited in eight cohorts up to doses of 150... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | MEK inhibitor | Phase I | Optimal biological dose | Pharmacokinetics | BRAF-MUTATED MELANOMA | MULTICENTER | SELUMETINIB PLUS DOCETAXEL | SAFETY | TRAMETINIB | CELL LUNG-CANCER | TRIAL | DOSE-ESCALATION | ONCOLOGY | DOUBLE-BLIND | AZD6244 ARRY-142886 | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Nausea - chemically induced | Allosteric Regulation | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Fatigue - chemically induced | Ribosomal Protein S6 Kinases, 70-kDa - drug effects | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - drug therapy | Chromatography, Liquid | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Bile Duct Neoplasms - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Administration, Oral | Carcinoma, Non-Small-Cell Lung - metabolism | Neoplasms - drug therapy | Maximum Tolerated Dose | Mesothelioma - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Anorexia - chemically induced | Glycogen Synthase Kinase 3 beta - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Neoplasms - metabolism | Phosphoproteins - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | Cholangiocarcinoma - metabolism | Chromatography, High Pressure Liquid | Diarrhea - chemically induced | Mitogen-Activated Protein Kinase 3 - drug effects | Pancreatic Neoplasms - drug therapy | Tandem Mass Spectrometry | Uterine Cervical Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Adult | Female | Colorectal Neoplasms - metabolism | Bile Duct Neoplasms - drug therapy | Drug Eruptions - etiology | Abdominal Pain - chemically induced | Uterine Cervical Neoplasms - drug therapy | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Cholangiocarcinoma - drug therapy | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - drug effects | Care and treatment | Protein kinases | Mitogens | Cells | Tumors
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 4, p. e61895
... efficacy. We hypothesized that the immunopotentiating effects of this drug are partly restrained by the inhibitory T cell molecule CTLA-4 and thus could be augmented by combining it with a blocking antibody... 
T-CELL RESPONSES | TUMOR-BEARING MICE | COMBINATION | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | Mesothelioma - immunology | Lung Neoplasms - drug therapy | Neoplasm Transplantation | CD8-Positive T-Lymphocytes - pathology | Mesothelioma - pathology | Lung Neoplasms - mortality | Carcinoma, Lewis Lung - immunology | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Mesothelioma - mortality | Lymphocyte Depletion | CD4-Positive T-Lymphocytes - pathology | CD4-Positive T-Lymphocytes - immunology | Drug Therapy, Combination | Immunity, Innate - drug effects | Antibodies, Monoclonal - pharmacology | Mice, Transgenic | Carcinoma, Lewis Lung - drug therapy | Mesothelioma - drug therapy | Drug Synergism | Lung Neoplasms - immunology | Animals | Tumor Burden - drug effects | Carcinoma, Lewis Lung - mortality | CD8-Positive T-Lymphocytes - drug effects | Survival Analysis | Carcinoma, Lewis Lung - pathology | Mice | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | Deoxycytidine - analogs & derivatives | Immunologic Factors - pharmacology | Antimitotic agents | Viral antibodies | Chemotherapy | Analysis | Lung cancer | Melanoma | Antibodies | Antineoplastic agents | T cells | Drug approval | Cancer | Ovarian cancer | Drugs | Animal models | Asbestos | Gemcitabine | Ovarian carcinoma | CD8 antigen | Blocking antibodies | Clinical trials | Cytotoxicity | Mesothelioma | Oncology | Lymphocytes T | Metastasis | Immunity | Cancer therapies | Immunosuppressive agents | Metastases | Ethics | CTLA-4 protein | Immunology | Lymphocytes | Immunotherapy | Drug dosages | Immune system | Medical research | Antigens | Immune response | Immunomodulation | T cell receptors | Breast cancer | Pharmacology | Patients | CD4 antigen | Medicine | Hospitals | Immune checkpoint | Immunogenicity | Synergistic effect | Nucleoside analogs | Apoptosis
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 10, pp. 1386 - 1396
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 2017, Volume 10, Issue 1, pp. 144 - 144
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2012, Volume 18, Issue 1, pp. 77 - 90
Purpose: Polycomb group (PcG) proteins are critical epigenetic mediators of stem cell pluripotency, which have been implicated in the pathogenesis of human... 
CELLS | METHYLATION | X-CHROMOSOME | GENE | ONCOLOGY | GROWTH | MALIGNANT PLEURAL MESOTHELIOMA | GROUP PROTEIN EED | EXPRESSION | CARCINOMA | EZH2 | RNA, Small Interfering - genetics | Pleural Neoplasms - genetics | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Humans | MicroRNAs - metabolism | Gene Expression Profiling | Immunoenzyme Techniques | Repressor Proteins - antagonists & inhibitors | Pleural Neoplasms - drug therapy | DNA-Binding Proteins - metabolism | Pleural Neoplasms - metabolism | Chromatin Immunoprecipitation | Biomarkers, Tumor - metabolism | Adult | Female | Real-Time Polymerase Chain Reaction | Repressor Proteins - metabolism | DNA-Binding Proteins - antagonists & inhibitors | RNA, Messenger - genetics | Cells, Cultured | Repressor Proteins - genetics | Transcription Factors - antagonists & inhibitors | Mesothelioma - genetics | Adenosine - pharmacology | Polycomb-Group Proteins | Transcription Factors - genetics | Cell Adhesion - drug effects | DNA-Binding Proteins - genetics | Blotting, Western | Enhancer of Zeste Homolog 2 Protein | Mesothelioma - drug therapy | Transcription Factors - metabolism | Cell Movement - drug effects | Polycomb Repressive Complex 2 | Animals | Mesothelioma - metabolism | Mice, Nude | Adenosine - analogs & derivatives | Aged | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | MicroRNAs - genetics | microarray | EED | polycomb | DZNep | mesothelioma | epigenetics
Journal Article